PARP Inhibitor for Ovarian Cancer Therapy

Abstract

Almost all ovarian cancers are comprised of epithelial ovarian cancer (EOC). Approximately 80% of patients with EOC initially respond to standard cytoreductive therapy and postoperative platinum-based chemotherapy. However, due to drug resistance in high-grade serous ovarian cancer (HGSOC), recurrence is almost inevitable. Recently, the nuclear enzyme poly (ADP ribose) polymerase (PARP) represents a surprisingly new target in EOC therapy. Inhibitors of PARP have demonstrated promising efficacy in the treatment of EOC. Studies on Olaparib, in particular, hastened its approval in the USA and Europe. The main topics of this study are the pre-clinical evidence, ongoing clinical studies, recent advancements in PARP inhibitor technology, and their potential future roles in clinical care for EOC patients.